Li Zi, Matzger Adam J
Department of Chemistry, Macromolecular Science and Engineering Program, University of Michigan , 930 North University Avenue, Ann Arbor, Michigan 48109-1055, United States.
Mol Pharm. 2016 Mar 7;13(3):990-5. doi: 10.1021/acs.molpharmaceut.5b00843. Epub 2016 Feb 3.
Cocrystallization is a technique to optimize solid forms that shows great potential to improve the solubility of active pharmaceutical ingredients (APIs). In some systems, an API can form cocrystals in multiple stoichiometries with the same coformer. However, it remains unclear how coformer stoichiometry influences solubility. This paper investigates the pharmaceutical:coformer pair carbamazepine (CBZ)/p-aminobenzoic acid (PABA); both CBZ/PABA 1:1 and 2:1 cocrystals are known, and a novel 4:1 CBZ/PABA cocrystal is reported here. The 4:1 cocrystal is structurally characterized, and phase stability data suggest that it is a thermodynamically unstable form. Dissolution experiments show that there is no correlation between the cocrystal stoichiometry and dissolution rate in this system. On the other hand, with the relatively weak intermolecular interactions, metastable forms can be beneficial to dissolution rate, which suggests that more effort should be devoted to cocrystal production with kinetic growth methods.
共结晶是一种优化固体形态的技术,在提高活性药物成分(API)的溶解度方面显示出巨大潜力。在某些体系中,一种API可以与同一共形成物以多种化学计量比形成共晶体。然而,共形成物的化学计量比如何影响溶解度仍不清楚。本文研究了药物:共形成物对卡马西平(CBZ)/对氨基苯甲酸(PABA);已知CBZ/PABA 1:1和2:1共晶体,本文报道了一种新型的4:1 CBZ/PABA共晶体。对4:1共晶体进行了结构表征,相稳定性数据表明它是一种热力学不稳定的形式。溶解实验表明,在该体系中共晶体化学计量比与溶解速率之间没有相关性。另一方面,由于分子间相互作用相对较弱,亚稳形式可能有利于溶解速率,这表明应该更多地致力于采用动力学生长方法制备共晶体。